Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00410410 · ClinicalTrials.gov registry record · Phase 3
A Study of Abatacept in Patients With Active Ulcerative Colitis
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 591
- Enrollment target
NCT00410410: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT00410410 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 591 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (23% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00410410, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 591 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to learn if abatacept can improve signs and symptoms of active ulcerative colitis in patients who have not had an adequate response to other therapies. The safety of this treatment will also be studied
Primary Outcome
The Mayo Scoring system ranges from 0 - 12 points and is a composite index consisting of 4 disease variables (stool frequency, rectal bleeding, endoscopy evaluation, and Physician's Global Assessment). Higher Mayo scores indicate greater severity of disease. A clinical response is defined as a reduction from baseline in the Mayo score of ≥ 3 points and ≥ 30%, with an accompanying decrease in the rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.
Interventions
- DRUG placebo
- DRUG abatacept
- DRUG abatacept (ABA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 591 participants |
| Start Date | 2006-12 |
| Est. Completion | 2009-11 |
| Phase | Phase 3 |
What the finished NCT00410410 record still lists
NCT00410410 is an interventional study that assigns participants to a tested intervention. The registered 591 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (23% lower).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00410410 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00410410 about?
NCT00410410 is a clinical study titled "A Study of Abatacept in Patients With Active Ulcerative Colitis". The purpose of this clinical research study is to learn if abatacept can improve signs and symptoms of active ulcerative colitis in patients who have not had an adequate response to other therapies. The safety of this treatment will also be studied
What is the current status of trial NCT00410410?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 591 participants. The study started on 2006-12. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00410410?
The interventions under investigation include: placebo (DRUG), abatacept (DRUG), abatacept (ABA) (DRUG).
Who is sponsoring clinical trial NCT00410410?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00410410's enrollment target sits among peer trials
591 643rd of 2000 higher than 1,358 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01365169 · 590 participants · NA
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
- NCT03774758 · 590 participants
Biomarkers for Risk Stratification in Lung Cancer
- NCT04747626 · 590 participants · NA
B-SAFER: Branched Stented Anastomosis Frozen Elephant Trunk Repair
- NCT05722938 · 590 participants · Phase 3
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia